Lilly Mark Selected Research

1- (2,3- dichlorobenzoyl)- 5- methoxy- 2- methyl- (2- (mopholin- 4- yl)ethyl)- 1H- indole

12/2005	A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
4/2005	Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lilly Mark Research Topics

Disease

6	Pain (Aches) 09/2010 - 07/2003
5	Hyperalgesia 09/2010 - 07/2003
4	Infections 01/2021 - 12/2013
3	Neuralgia (Stump Neuralgia) 09/2009 - 07/2003
2	Staphylococcal Infections 01/2016 - 12/2013
2	Ataxia (Dyssynergia) 12/2005 - 04/2005
2	Chronic Pain 12/2005 - 04/2005
2	Catalepsy 12/2005 - 04/2005
2	Inflammation (Inflammations) 04/2005 - 08/2004
1	Cystic Fibrosis (Mucoviscidosis) 01/2021
1	Bacterial Infections (Bacterial Infection) 01/2016
1	Ulcer 09/2010
1	Hypersensitivity (Allergy) 09/2010
1	Postoperative Pain 08/2004

Drug/Important Bio-Agent (IBA)

3	Analgesics (Analgesic Drugs)IBA 12/2005 - 07/2003
2	Methicillin (Metin)FDA Link 12/2013 - 12/2013
2	Indomethacin (Indometacin)FDA LinkGeneric 09/2010 - 01/2004
2	CB2 Cannabinoid ReceptorIBA 12/2005 - 04/2005
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 12/2005 - 04/2005
2	1- (2,3- dichlorobenzoyl)- 5- methoxy- 2- methyl- (2- (mopholin- 4- yl)ethyl)- 1H- indoleIBA 12/2005 - 04/2005
1	LipoglycopeptidesIBA 01/2021
1	Vancomycin FDA LinkGeneric 01/2021
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2021
1	Cefdinir (Omnicef)FDA LinkGeneric 01/2016
1	ProdrugsIBA 01/2016
1	Pharmaceutical PreparationsIBA 01/2016
1	TXA709IBA 01/2016
1	N- (3- ((6- chlorothiazolo(5,4- b)pyridin- 2- yl)methoxy)- 2,6- difluorobenzoyl)- 1- methylpiperidine- 4- carboxamideIBA 12/2013
1	TXY436IBA 12/2013
1	benzamideIBA 12/2013
1	PC190723IBA 12/2013
1	SaporinsIBA 09/2010
1	Adrenocorticotropic Hormone (ACTH)FDA Link 09/2010
1	CarrageenanIBA 09/2010
1	CP 154526IBA 09/2010
1	2- methyl- 4- (N- propyl- N- cycloproanemethylamino)- 5- chloro- 6- (2,4,6- trichloranilino)pyrimidineIBA 09/2010
1	compound 20IBA 09/2009
1	Lamotrigine (Lamictal)FDA LinkGeneric 09/2006
1	Carbamazepine (Tegretol)FDA LinkGeneric 09/2006
1	Sodium Channel BlockersIBA 09/2006
1	pyrimidineIBA 09/2006
1	CannabinoidsIBA 12/2005
1	Cannabinoid Receptor AgonistsIBA 04/2005
1	Opioid Analgesics (Opioids)IBA 08/2004
1	mu Opioid Receptors (mu Opioid Receptor)IBA 08/2004
1	Naltrexone (ReVia)FDA LinkGeneric 08/2004
1	EtoricoxibIBA 01/2004
1	Naproxen (Naprosyn)FDA LinkGeneric 01/2004
1	Gabapentin (Neurontin)FDA LinkGeneric 01/2004
1	Celecoxib (Celebrex)FDA Link 01/2004
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2004
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2004
1	Morphine (MS Contin)FDA LinkGeneric 01/2004
1	Capsaicin (Zostrix)FDA Link 07/2003
1	TRPV Cation ChannelsIBA 07/2003
1	LigandsIBA 07/2003
1	CationsIBA 07/2003
1	capsazepineIBA 07/2003

Therapy/Procedure

2	Therapeutics 01/2016 - 09/2006
2	Oral Administration 01/2016 - 09/2010
2	Ligation 09/2009 - 09/2006
1	Analgesia 04/2005